dc.contributor
Institut Català de la Salut
dc.contributor
[Pellegrino B, Musolino A] Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [De Silva P] Molecular Immunology Unit, Institut Jules Bordet and Universite Libre de Bruxelles, Bruxelles, Belgium. [Hlavata Z] Medical Oncology Department, CHR Mons-Hainaut, Mons, Belgium
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Pellegrino, B.
dc.contributor.author
Musolino, Antonio
dc.contributor.author
Llop Guevara, Alba
dc.contributor.author
Serra Elizalde, Violeta
dc.contributor.author
De Silva, P.
dc.contributor.author
Hlavata, Z.
dc.date.accessioned
2025-10-25T05:37:02Z
dc.date.available
2025-10-25T05:37:02Z
dc.date.issued
2021-10-27T12:55:34Z
dc.date.issued
2021-10-27T12:55:34Z
dc.date.issued
2020-02-01
dc.identifier
Pellegrino B, Musolino A, Llop-Guevara A, Serra V, De Silva P, Hlavata Z, et al. Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Transl Oncol. 2020 Feb 1;13(2):410–22.
dc.identifier
https://hdl.handle.net/11351/6474
dc.identifier
10.1016/j.tranon.2019.10.010
dc.identifier
000513932000032
dc.identifier.uri
http://hdl.handle.net/11351/6474
dc.description.abstract
Càncer de mama; Immunoteràpia; Danys en l’ADN
dc.description.abstract
Cáncer de mama; Inmunoterapia; Daño en el ADN
dc.description.abstract
Breast Cancer; Immunotherapy; DNA damage
dc.description.abstract
The success of cancer immunotherapy with immune checkpoint blockade (ICB) has demonstrated the importance of targeting a preexisting immune response in a broad spectrum of tumors. This is particularly novel and relevant for less immunogenic tumors, such as breast cancer (BC), where the efficacy of ICB was more evident in the triple-negative (TNBC) subtype, in earlier stages, and in association with chemotherapy. Tumors harboring homologous recombination DNA repair (HRR) deficiency (HRD) are supposed to have a higher number of mutations, hence a higher tumor mutational burden, which could potentially make them more sensitive to immunotherapy. However, the mechanisms involved in ICB sensitivity and patient selection are still yet to be defined in BC: whether the innate system could play a role and how the adaptive immunity could be linked with HRR pathways are the two key points of debate that we will discuss in this article. The aim of this review was to close the loop between what was found in clinical trial results so far, go back to laboratory theory and preclinical results and point out what needs to be clarified from now on.
dc.description.abstract
B.P. was supported by European Society of Medical Oncology ( ESMO) with the aid of a grant from Roche.
dc.format
application/pdf
dc.relation
Translational Oncology;13(2)
dc.relation
https://doi.org/10.1016/j.tranon.2019.10.010
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
ADN - Reparació
dc.subject
Mama - Càncer - Immunoteràpia
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::/therapy
dc.subject
PHENOMENA AND PROCESSES::Chemical Phenomena::Biochemical Phenomena::DNA Repair::Recombinational DNA Repair
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::/terapia
dc.subject
FENÓMENOS Y PROCESOS::fenómenos químicos::fenómenos bioquímicos::reparación del ADN::reparación del ADN por recombinación
dc.title
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
